Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy
Open Access
- 12 June 2015
- journal article
- review article
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 10 (1) , 17
Abstract
Currently, there is limited data on the immunogenicity and efficacy of human papillomavirus vaccines in Low and Middle income countries (LMIC). The review aims to summarize the current status from published HPV vaccine safety, immunogenicity and efficacy studies in low and middle income countries (LMIC). Electronic databases (PubMed/MEDLINE and HINARI) were searched for peer reviewed English language articles on HPV vaccination in LMIC that have so far been published from 1st January 2006 up to 30th January 2015. Eligible studies were included if they had used the bivalent (bHPV) or quadrivalent HPV (qHPV) vaccines in a LMIC and investigated safety, immunogenicity and/or efficacy. The main findings were extracted and summarized. A total of fourteen HPV vaccine studies assessing safety, Immunogenicity and efficacy of the bivalent or quadrivalent vaccines in LMIC were included. There are only ten published clinical trials where a LMIC has participated. There was no published study so far that assessed efficacy of the HPV vaccines in Sub-Saharan Africa. From these studies, vaccine induced immune response was comparable to that from results of HICs for all age groups. Studies assessing HPV vaccine efficacy of the bivalent or quadrivalent vaccine within LMIC were largely missing. Only three studies were found where a LMIC was part of a multi center clinical trial. In all the studies, there were no vaccine related serious adverse events. The findings from the only study that investigated less than three doses of the bivalent HPV-16/18 vaccine suggest that even with less than three doses, antibody levels were still comparable with older women where efficacy has been proven. The few studies from LMIC in this review had comparable safety, Immunogenicity and efficacy profiles like in HIC. Overall, the LMIC of Africa where immune compromising/modulating situations are prevalent, there is need for long term immunogenicity as well as surveillance studies for long term clinical effectiveness after two and three dose regimens.Keywords
This publication has 38 references indexed in Scilit:
- Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospectsVaccine, 2013
- Immunogenicity of Quadrivalent HPV Vaccine Among Girls 11 to 13 Years of Age Vaccinated Using Alternative Dosing Schedules: Results 29 to 32 Months After Third DoseThe Journal of Infectious Diseases, 2013
- A Review of Clinical Trials of Human Papillomavirus Prophylactic VaccinesVaccine, 2012
- Human Papillomavirus Vaccination in Tanzanian Schoolgirls: Cluster-Randomized Trial Comparing 2 Vaccine-Delivery StrategiesThe Journal of Infectious Diseases, 2012
- Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young WomenThe Journal of Infectious Diseases, 2012
- Cervical Cancer Screening in the United States and the Netherlands: A Tale of Two CountriesThe Milbank Quarterly, 2012
- Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of BangladeshJapanese Journal of Clinical Oncology, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Expansion of cancer care and control in countries of low and middle income: a call to actionThe Lancet, 2010
- Ethical and Scientific Implications of the Globalization of Clinical ResearchNew England Journal of Medicine, 2009